Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1.08B
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
15.9M
-
Shares change
-
+15.9M
-
Total reported value, excl. options
-
$378M
-
Value change
-
+$377M
-
Put/Call ratio
-
2.13
-
Number of buys
-
108
-
Price
-
$23.74
Significant Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q1 2021
123 filings reported holding IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share as of Q1 2021.
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.9M shares
of 1.08B outstanding shares and own 1.48% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.55M shares), VANGUARD GROUP INC (2.56M shares), STATE STREET CORP (2.33M shares), GEODE CAPITAL MANAGEMENT, LLC (665K shares), JPMORGAN CHASE & CO (544K shares), Rafferty Asset Management, LLC (525K shares), NORTHERN TRUST CORP (482K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (470K shares), HarbourVest Partners LLC (347K shares), and MORGAN STANLEY (333K shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.